Abstract
Augmented Acute Normovolemic Hemodilution serves to reduce the need for allogeneic blood transfusions in patients undergoing high blood loss surgery. Augmented acute normovolemic hemodilution has 3 phases: First, acute normovolemic hemodilution prior to surgical blood loss, second, administration of an artificial O2 carrier such as a modified hemoglobin solution or perflubron emulsion during periods of low endogenous hemoglobin concentration during surgery and third, re-transfusion of autologous blood after the operation. Efficacy remains to be ultimately proven in clinical trials but mathematical modeling indicates that clinically significant reductions in allogeneic blood transfusions are likely.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
